Faron Pharmaceuticals Ltd said it plans to host a virtual R&D day via webcast next week, where chief executive Dr Markku Jalkanen will host the event together with members of the management team and external experts.
The event will be held on 23 February at 4pm EET (2pm GMT, 9am EDT).
The external experts provide additional perspectives are Dr Tyler Curiel, Professor of Medicine and Microbiology, Immunology & Molecular Genetics at The University of Texas Health Science Center, and Dr Maija Hollmén, Adjunct Professor of Tumour Immunology, Group Leader and Academy Research Fellow at the MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Finland.
Faron's new chief medical officer, Dr Marie-Louise Fjällskog, will provide an update on bexmarilimab, the company's wholly-owned novel precision cancer immunotherapy in Phase I/II development.
There will be an opportunity to ask questions during the webcast, Faron said, with registration available on the company's website here.